Upgrade to SI Premium - Free Trial

Acadia Pharma (ACAD) Higher as Leerink Highlights as Partnership and Acquisition Target

April 14, 2016 9:57 AM
Acadia Pharma (NASDAQ: ACAD) is solidly higher early Thursday (+3.2%) after Leerink Partners analyst Joseph Schwartz highlighted the company as ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Rumors Trader Talk

Next Articles